Induction of mucosal and systemic antibody specific for SeMF3 of Streptococcus equi by intranasal vaccination using a sucrose acetate isobutyrate based delivery system

被引:21
作者
Nally, JE
Artiushin, S
Sheoran, AS
Burns, PJ
Simon, B
Gilley, RM
Gibson, J
Sullivan, S
Timoney, JF [1 ]
机构
[1] Univ Kentucky, Maxwell H Gluck Equine Res Ctr 108, Lexington, KY 40546 USA
[2] Thorn Biosci LLC, Lexington, KY USA
[3] So Biosyst Inc, Birmingham, AL USA
关键词
intranasal immunization; sucrose acetate isobutyrate; equine immunoglobulin;
D O I
10.1016/S0264-410X(00)00187-0
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Streptococcus equi causes equine strangles, a highly contagious disease of the upper respiratory tract. The antiphagocytic surface protein SeM is strongly immunogenic and evokes mucosal and systemic antibodies during convalescence. The present study investigated the potential of sucrose acetate isobutyrate (SAIB); a high viscosity excipient that provides controlled release of biologically active substances, to enhance antibody responses following intranasal immunization of horses with a 108 a.a. peptide of SeM (SeMF3). SeMF3-SAIB was administered intranasally to each of the 11 adult horses on days 0 and 28, A second group of seven horses was vaccinated with SeMF3 alone. SAIB enhanced the mucosal and systemic immunogenicity of SeMF3, whereas SeMF3 by itself stimulated only a shortlived mucosal IgA and no systemic response. Moreover, nasal mucosal responses of horses immunized with SeMF3-SAIB were qualitatively and quantitatively similar to those observed in convalescent horses and involved similar linear epitopes of SeM. Epitope analysis also suggested that the nasal response was different from that observed in serum. A booster response was obtained after the second vaccination. These results suggest that SAIB has potential as a vehicle for intranasal immunization of horses with antigenic peptides. (C) 2000 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:492 / 497
页数:6
相关论文
共 17 条
[1]  
Berneman A, 1998, INFECT IMMUN, V66, P4163
[2]   CHARACTERIZATION OF THE ANTIPHAGOCYTIC ACTIVITY OF EQUINE FIBRINOGEN FOR STREPTOCOCCUS-EQUI SUBSP EQUI [J].
BOSCHWITZ, JS ;
TIMONEY, JF .
MICROBIAL PATHOGENESIS, 1994, 17 (02) :121-129
[3]   INHIBITION OF C3 DEPOSITION ON STREPTOCOCCUS-EQUI SUBSP EQUI BY M-PROTEIN - A MECHANISM FOR SURVIVAL IN EQUINE BLOOD [J].
BOSCHWITZ, JS ;
TIMONEY, JF .
INFECTION AND IMMUNITY, 1994, 62 (08) :3515-3520
[4]   Diversity of antibody-mediated immunity at the mucosal barrier [J].
Bouvet, JP ;
Fischetti, VA .
INFECTION AND IMMUNITY, 1999, 67 (06) :2687-2691
[5]   PASSIVE TRANSFER OF MUCOSAL ANTIBODY TO STREPTOCOCCUS-EQUI IN THE FOAL [J].
GALAN, JE ;
TIMONEY, JF ;
LENGEMANN, FW .
INFECTION AND IMMUNITY, 1986, 54 (01) :202-206
[6]   MUCOSAL NASOPHARYNGEAL IMMUNE-RESPONSES OF HORSES TO PROTEIN ANTIGENS OF STREPTOCOCCUS-EQUI [J].
GALAN, JE ;
TIMONEY, JF .
INFECTION AND IMMUNITY, 1985, 47 (03) :623-628
[7]  
HAMLEN HJ, 1994, J AM VET MED ASSOC, V204, P768
[8]  
LUNN DP, 1998, HDB VERTEBRATE IMMUN, P343
[9]  
LUNN DP, 1998, VET IMMUNOL IMMUNOP, V42, P3
[10]  
McGuire T. C., 1973, Equine diseases III,, P364